{"id":"lovastatin-tablet","safety":{"commonSideEffects":[{"rate":"2-5","effect":"Myalgia (muscle pain)"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"2-4","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"1-3","effect":"Gastrointestinal disturbance"}]},"_chembl":{"chemblId":"CHEMBL1201373","moleculeType":"Small molecule","molecularWeight":"422.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lovastatin is a competitive inhibitor of HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis. By blocking this enzyme, lovastatin decreases intracellular cholesterol production, leading to upregulation of LDL receptors on hepatocytes and increased clearance of LDL cholesterol from the bloodstream. This results in significant reductions in serum LDL and total cholesterol levels.","oneSentence":"Lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:07.663Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"},{"name":"Primary prevention of coronary heart disease"},{"name":"Secondary prevention of coronary heart disease"}]},"trialDetails":[{"nctId":"NCT06566794","phase":"NA","title":"KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2024-08-22","conditions":"Drug Interaction","enrollment":12},{"nctId":"NCT05771675","phase":"EARLY_PHASE1","title":"Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2024-10-24","conditions":"Recurrent Acute Pancreatitis, Chronic Pancreatitis","enrollment":90},{"nctId":"NCT00858637","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-03","conditions":"Chronic Kidney Disease","enrollment":260},{"nctId":"NCT03654053","phase":"PHASE3","title":"Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-10-02","conditions":"Cirrhosis","enrollment":142},{"nctId":"NCT07256561","phase":"NA","title":"Antimicrobial and Anti-inflammatory Effects of Simvastatin as an Intracanal Medication","status":"RECRUITING","sponsor":"Hadeer Maher Mostafa Mohamed","startDate":"2025-08-10","conditions":"Endodontically Retard Teeth, Periapical Radiolucency","enrollment":54},{"nctId":"NCT02197234","phase":"PHASE1","title":"Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-22","conditions":"Non Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT06948747","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-06","conditions":"Healthy Participants","enrollment":49},{"nctId":"NCT04133792","phase":"PHASE3","title":"Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Annika Bergquist","startDate":"2020-10-01","conditions":"Primary Sclerosing Cholangitis","enrollment":571},{"nctId":"NCT03400826","phase":"PHASE2","title":"Effects of Simvastatin on Uterine Leiomyoma Size","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-08-20","conditions":"Fibroid Uterus, Fibroid Tumor, Leiomyoma","enrollment":60},{"nctId":"NCT03896217","phase":"PHASE2","title":"Simvastatin in Secondary Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"University College, London","startDate":"2019-05-16","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":40},{"nctId":"NCT02964884","phase":"PHASE2","title":"Interventions for Reading Disabilities in NF1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2016-11","conditions":"Neurofibromatosis Type 1, Learning Disability, Reading Disability","enrollment":120},{"nctId":"NCT07003815","phase":"PHASE2","title":"Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06","conditions":"Biliary Tract Cancer, Advanced Cancer","enrollment":62},{"nctId":"NCT04301271","phase":"PHASE2","title":"Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2020-08-13","conditions":"Depressive Disorder, Major, Obesity","enrollment":161},{"nctId":"NCT04971577","phase":"PHASE2, PHASE3","title":"Efficacy of Simvastatin in Alcoholic Liver Fibrosis","status":"RECRUITING","sponsor":"Anna Cruceta","startDate":"2022-02-22","conditions":"Liver Fibrosis, Alcohol Abuse","enrollment":90},{"nctId":"NCT03387670","phase":"PHASE3","title":"Multiple Sclerosis-Simvastatin Trial 2","status":"COMPLETED","sponsor":"University College, London","startDate":"2018-03-28","conditions":"Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":964},{"nctId":"NCT00092651","phase":"PHASE3","title":"A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09","conditions":"Hypercholesterolemia","enrollment":1398},{"nctId":"NCT00541697","phase":"PHASE3","title":"Eze/Simva Switch Study in Diabetics (0653A-807)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-19","conditions":"Diabetes Mellitus, Type 2","enrollment":648},{"nctId":"NCT00552097","phase":"PHASE3","title":"Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-06-01","conditions":"Atherosclerosis, Hypercholesterolemia, Hyperlipoproteinemia Type II","enrollment":720},{"nctId":"NCT00092664","phase":"PHASE3","title":"An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-01","conditions":"Hypercholesterolemia","enrollment":1104},{"nctId":"NCT00090298","phase":"PHASE3","title":"Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-04","conditions":"Hypercholesterolemia","enrollment":2815},{"nctId":"NCT00650663","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-10-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":247},{"nctId":"NCT00132717","phase":"PHASE3","title":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Hypercholesterolemia","enrollment":450},{"nctId":"NCT00398294","phase":"PHASE4","title":"To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05-01","conditions":"Hypercholesterolemia","enrollment":30},{"nctId":"NCT00653835","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-01","conditions":"Hypercholesterolaemia, Atherosclerosis","enrollment":153},{"nctId":"NCT00110435","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":1229},{"nctId":"NCT00652301","phase":"PHASE3","title":"A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-07","conditions":"Cholesterol","enrollment":40},{"nctId":"NCT00166530","phase":"PHASE4","title":"EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Atherosclerosis","enrollment":367},{"nctId":"NCT00651391","phase":"PHASE3","title":"Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2003-10-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":28},{"nctId":"NCT03011931","phase":"EARLY_PHASE1","title":"Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]","status":"COMPLETED","sponsor":"Entero Therapeutics","startDate":"2016-03","conditions":"Celiac Disease","enrollment":40},{"nctId":"NCT06186622","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-01-02","conditions":"Healthy, Obese, Overweight","enrollment":50},{"nctId":"NCT00202878","phase":"PHASE3","title":"IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-10-17","conditions":"Hypercholesterolemia, Myocardial Infarction","enrollment":18144},{"nctId":"NCT00739050","phase":"PHASE4","title":"Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-09-19","conditions":"Systemic Lupus Erythematosus","enrollment":4},{"nctId":"NCT00442897","phase":"PHASE4","title":"Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Hypercholesterolemia","enrollment":229},{"nctId":"NCT00654628","phase":"PHASE4","title":"Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-08-01","conditions":"Hypercholesterolemia","enrollment":173},{"nctId":"NCT00423579","phase":"PHASE4","title":"The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-07-01","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":120},{"nctId":"NCT00496730","phase":"PHASE3","title":"A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-07","conditions":"Hypercholesterolemia","enrollment":256},{"nctId":"NCT00535405","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Hypercholesterolemia","enrollment":1289},{"nctId":"NCT00409773","phase":"PHASE3","title":"Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia, Metabolic Syndrome","enrollment":1143},{"nctId":"NCT00782184","phase":"PHASE3","title":"Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11","conditions":"Hypercholesterolemia","enrollment":250},{"nctId":"NCT00462748","phase":"PHASE3","title":"A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-03","conditions":"Hypercholesterolemia","enrollment":786},{"nctId":"NCT00479713","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-02-01","conditions":"Hypercholesterolemia","enrollment":618},{"nctId":"NCT00271817","phase":"PHASE3","title":"To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":1220},{"nctId":"NCT00862251","phase":"PHASE3","title":"Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-04","conditions":"Cardiovascular Disorder, Diabetes Mellitus","enrollment":808},{"nctId":"NCT00092690","phase":"PHASE3","title":"MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-06","conditions":"Hypercholesterolemia","enrollment":1902},{"nctId":"NCT03884452","phase":"PHASE3","title":"Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-05-03","conditions":"Familial Hypercholesterolemia","enrollment":50},{"nctId":"NCT01764451","phase":"EARLY_PHASE1","title":"Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2012-03","conditions":"Cavernous Angioma, Familial, Cerebral Cavernous Malformations, Cerebral Cavernous Hemangioma","enrollment":12},{"nctId":"NCT06178640","phase":"PHASE1","title":"Bioequivalence Study of Simvastatin 40 mg Film-coated Tablets in Healthy Thai Volunteers","status":"UNKNOWN","sponsor":"International Bio service","startDate":"2024-08-13","conditions":"Healthy Volunteer","enrollment":46},{"nctId":"NCT06207682","phase":"PHASE1","title":"Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin","status":"COMPLETED","sponsor":"Amgen","startDate":"2022-06-28","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT00988364","phase":"PHASE4","title":"Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2007-03","conditions":"Metabolic Syndrome","enrollment":30},{"nctId":"NCT05750602","phase":"NA","title":"Combined Effect of LIMICOL and Physical Activity on LDL Cholesterol and Muscle Function.","status":"COMPLETED","sponsor":"Lescuyer Laboratory","startDate":"2013-11","conditions":"Hypercholesterolemia","enrollment":40},{"nctId":"NCT05682911","phase":"EARLY_PHASE1","title":"Protective Effect of Zingiber Officinale L. Extract in Hypertensive Patients","status":"COMPLETED","sponsor":"Jinnah Sindh Medical University","startDate":"2018-01-01","conditions":"The Main Focus of This Study is to Evaluate the Safety of Zingiber Officinale L. Tablets as Hypolipidemic Agent in Hypertensive Patients","enrollment":40},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":1000},{"nctId":"NCT05613400","phase":"PHASE4","title":"Statin and Bone Health","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-04-13","conditions":"Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT00302952","phase":"PHASE2","title":"Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-11-06","conditions":"Rheumatoid Arthritis","enrollment":64},{"nctId":"NCT05369091","phase":"PHASE4","title":"Salivary Bmp-2 Levels & Radiographic Measurement Of Bone Density at Extracted Tooth","status":"COMPLETED","sponsor":"Postgraduate Medical Institute, Lahore","startDate":"2020-12-16","conditions":"Bone Injury","enrollment":24},{"nctId":"NCT05306379","phase":"PHASE1","title":"Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin","status":"COMPLETED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2022-01-24","conditions":"Drug-drug Interaction","enrollment":24},{"nctId":"NCT01587235","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-03","conditions":"Dyslipidemia","enrollment":""},{"nctId":"NCT03885921","phase":"PHASE3","title":"Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-25","conditions":"Hypercholesterolemia","enrollment":44},{"nctId":"NCT00652431","phase":"PHASE1","title":"Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":18},{"nctId":"NCT00423488","phase":"PHASE3","title":"Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07-12","conditions":"Hypercholesterolemia, Diabetes Mellitus, Type 2, Coronary Disease","enrollment":93},{"nctId":"NCT00724477","phase":"","title":"Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-10","conditions":"Primary Hypercholesterolemia","enrollment":1663},{"nctId":"NCT00909389","phase":"","title":"Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-11","conditions":"Hypercholesterolemia","enrollment":4748},{"nctId":"NCT01952288","phase":"PHASE4","title":"Simvastatin for mTBI","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2013-09-16","conditions":"TBI-Traumatic Brain Injury","enrollment":5},{"nctId":"NCT03435744","phase":"PHASE3","title":"Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.","status":"COMPLETED","sponsor":"Pakistan Institute of Living and Learning","startDate":"2019-01-01","conditions":"Treatment Resistant Depression, Major Depressive Disorder","enrollment":150},{"nctId":"NCT04985201","phase":"PHASE2","title":"Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-11-01","conditions":"Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT04698941","phase":"PHASE2","title":"Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-07-25","conditions":"Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT04859452","phase":"PHASE1","title":"A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-05-26","conditions":"Healthy Subjects","enrollment":56},{"nctId":"NCT01953835","phase":"PHASE1","title":"A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-04","conditions":"Systemic Lupus Erythematosus","enrollment":37},{"nctId":"NCT00720577","phase":"EARLY_PHASE1","title":"Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease.","status":"COMPLETED","sponsor":"Medtronic Endovascular","startDate":"2005-12","conditions":"Peripheral Arterial Disease","enrollment":164},{"nctId":"NCT04301336","phase":"PHASE2, PHASE3","title":"Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-11-01","conditions":"Vaso-occlusive Crisis, Sickle Cell Disease, Sickle Cell Anemia in Children","enrollment":350},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT01999309","phase":"PHASE3","title":"Simvastatin Addition for Patients With Recent-onset Schizophrenia","status":"COMPLETED","sponsor":"Iris Sommer","startDate":"2013-10","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":121},{"nctId":"NCT00879710","phase":"NA","title":"Effect of Diabetes Mellitus on Cholesterol Metabolism","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2008-08","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":57},{"nctId":"NCT02587390","phase":"PHASE1","title":"Effect of Gemcabene on the Pharmacokinetics of Simvastatin in Healthy Volunteers","status":"COMPLETED","sponsor":"NeuroBo Pharmaceuticals Inc.","startDate":"2000-05","conditions":"Hypercholesterolemia","enrollment":20},{"nctId":"NCT03653663","phase":"PHASE4","title":"NIRS to Diagnose SAMS","status":"UNKNOWN","sponsor":"Hartford Hospital","startDate":"2018-01-01","conditions":"Statin Adverse Reaction, Skeletal Myopathy","enrollment":40},{"nctId":"NCT00842920","phase":"PHASE4","title":"Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2008-12","conditions":"Mild Cognitive Impairment","enrollment":520},{"nctId":"NCT01420549","phase":"PHASE3","title":"Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2013-03","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":129},{"nctId":"NCT00647348","phase":"PHASE2","title":"Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2008-01","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":140},{"nctId":"NCT02406261","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-04-30","conditions":"Healthy","enrollment":82},{"nctId":"NCT03739242","phase":"NA","title":"Effect of a Treatment With a Nutraceutical Combination on Sub-optimal LDL Cholesterol Levels","status":"COMPLETED","sponsor":"A. Menarini Industrie Farmaceutiche Riunite S.r.l.","startDate":"2017-10-12","conditions":"Hypercholesterolemia","enrollment":88},{"nctId":"NCT00180713","phase":"PHASE1, PHASE2","title":"Simvastatin as a Treatment for Pulmonary Hypertension","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2005-10","conditions":"Pulmonary Hypertension","enrollment":42},{"nctId":"NCT03340285","phase":"NA","title":"Effects of a New Combination of Nutraceuticals (AkP06) Without Monacolin K on Plasma Lipids and Glucose","status":"COMPLETED","sponsor":"Federico II University","startDate":"2017-12-01","conditions":"Cardiovascular Risk Factor","enrollment":45},{"nctId":"NCT00486044","phase":"PHASE2","title":"Evaluating Simvastatin's Potential Role in Therapy","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2005-02","conditions":"Alzheimer Disease","enrollment":103},{"nctId":"NCT00479882","phase":"PHASE3","title":"MK-0524B Lipid Study (MK-0524B-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":2414},{"nctId":"NCT01335997","phase":"PHASE3","title":"Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1139},{"nctId":"NCT02142569","phase":"PHASE2, PHASE3","title":"Effects of a Supplement Derived From Palm Oil on Cholesterol Levels and Chinese Red Yeast Rice in the Blood","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2013-10-30","conditions":"Cholesterol Lowering","enrollment":""},{"nctId":"NCT02680379","phase":"PHASE2","title":"Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2016-03","conditions":"Fragile X Syndrome","enrollment":22},{"nctId":"NCT03490097","phase":"PHASE2, PHASE3","title":"Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2017-12-01","conditions":"Chronic Hepatitis c, Metabolic Syndrome","enrollment":100},{"nctId":"NCT00289900","phase":"PHASE3","title":"Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01-24","conditions":"Mixed Hyperlipidemia","enrollment":2340},{"nctId":"NCT01702298","phase":"PHASE3","title":"A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":42},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT01294683","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02-04","conditions":"Primary Hypercholesterolemia, Dyslipidemia","enrollment":977},{"nctId":"NCT03375580","phase":"NA","title":"Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangdong Pharmaceutical University","startDate":"2017-12-31","conditions":"Nonalcoholic Fatty Liver Disease","enrollment":196},{"nctId":"NCT03329118","phase":"PHASE1","title":"Drug-drug Interaction Between Simvastatin and SHR3824","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-11-24","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT02252328","phase":"PHASE2, PHASE3","title":"Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients","status":"UNKNOWN","sponsor":"University College, London","startDate":"2015-09","conditions":"Uveitis","enrollment":50},{"nctId":"NCT00495729","phase":"PHASE1","title":"15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-18","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":36},{"nctId":"NCT00504439","phase":"PHASE1","title":"A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":36},{"nctId":"NCT01142336","phase":"PHASE4","title":"Effects of Simvastatin on Biomarkers","status":"COMPLETED","sponsor":"University of Washington","startDate":"2010-06","conditions":"Alzheimer's Disease","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Group A"],"phase":"marketed","status":"active","brandName":"Lovastatin Tablet","genericName":"Lovastatin Tablet","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia, Primary prevention of coronary heart disease, Secondary prevention of coronary heart disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}